Jose Rivera Pozo-rekin lankidetzan egindako argitalpenak (10)

2018

  1. Temporal changes in platelet response in acute coronary syndrome patients with prasugrel and clopidogrel after stent implantation

    Circulation Journal, Vol. 82, Núm. 2, pp. 353-360

2016

  1. Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold

    Platelets, Vol. 27, Núm. 8, pp. 777-783

2012

  1. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome

    Revista Espanola de Cardiologia, Vol. 65, Núm. 3, pp. 219-226

  2. New perspectives in antiplatelet therapy

    Current Medicinal Chemistry, Vol. 19, Núm. 3, pp. 406-427

2009

  1. Does the Holy Grail escape us again?

    European Heart Journal

2008

  1. TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction

    Thrombosis and Haemostasis

2003

  1. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction

    American Journal of Cardiology, Vol. 91, Núm. 10, pp. 1242-1245

  2. The -1C>T mutation in the annexin A5 gene does not affect plasma levels of annexin A5 [2] (multiple letters)

    Blood

2002

  1. A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients

    Blood, Vol. 100, Núm. 6, pp. 2081-2086

  2. Effect of factor XIII VAL34LEU polymorphism on thrombolytic therapy in premature myocardial infarction

    Thrombosis and Haemostasis